The patient was a 52-year-old male, who, after experiencing lower back pain, underwent further investigation and was diagnosed with hepatocellular carcinoma with sacral metastasis. The hepatocellular carcinoma was a 9 cm tumor with a risk of rupture. Liver resection was performed, and lenvatinib was initiated at a dose of 4 mg/day postoperatively. Radical radiation therapy was then administered to address bone metastases. Lenvatinib was discontinued after 15 months due to skin disorders. Seven months have passed since the discontinuation of lenvatinib and 2 years since surgery. The patient's condition has progressed without any recurrence.